LLY Jun 2024 370.000 call
| Previous close | 173.02 |
| Open | 172.96 |
| Bid | 220.35 |
| Ask | 227.75 |
| Strike | 370.00 |
| Expiry date | 2024-06-21 |
| Day's range | 172.96 - 173.02 |
| Contract range | N/A |
| Volume | |
| Open interest | 77 |
Insider Monkey13 Best Jim Cramer Stocks To Buy Now
In this article, we will take a look at the 13 best Jim Cramer stocks to buy now. To see more such companies, go directly to 5 Best Jim Cramer Stocks To Buy Now. Jim Cramer recently talked about the latest market declines and said the buyers are going through a “hangover,” buying the “worst […]
PR NewswireLilly to Present Final Overall Survival Analysis from the MONARCH 3 Study of Verzenio® (abemaciclib) and Additional Results from Its Breast Cancer Portfolio at the 2023 San Antonio Breast Cancer Symposium
Eli Lilly and Company (NYSE: LLY) today announced results from the MONARCH 3 clinical trial, which will be presented in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (SABCS). MONARCH 3 evaluated Verzenio® (abemaciclib) in combination with an aromatase inhibitor (AI) compared to an AI alone as initial endocrine-based therapy for post-menopausal patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or me
ReutersEli Lilly obesity drug now available in US pharmacies
(Reuters) -Eli Lilly on Tuesday said its recently approved obesity treatment Zepbound is now available in U.S. pharmacies and could cost $550 a month for customers whose health insurance does not cover the drug, or half the list price. Wall Street analysts expect sales of Zepbound to reach about $2 billion in 2024, and for sales of Novo Nordisk's rival obesity drug Wegovy to hit around $7.5 billion. Pfizer last week said it would not advance its highly-anticipated oral obesity drug danuglipron into late-stage clinical trials after most patients dropped out of a midstage trial with high rates of side effects such as nausea and vomiting.
